A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Researchers reveal that metabolic enzymes known for their roles in energy production and nucleotide synthesis are taking on unexpected 'second jobs' within the nucleus, orchestrating critical ...

News in early breast cancer this year was marked by updated U.S. Preventive Services Task Force (USPSTF) screening ...

Among the many impactful sessions, a symposium titled ‘Incorporating Novel Treatment Insights for Estrogen Receptor-Positive (ER+) Early Breast Cancer Patients’ garnered particular attention.

This industry symposium took place during the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain, from 13 th –17 th September 2024. Schmid has received consulting fees from ...

for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients with hormone receptor-positive/human epidermal ...

for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) adjuvant therapy for patients with hormone receptor-positive/human epidermal ...

Neoadjuvant and adjuvant therapy for early-stage breast cancer Research ... of adjuvant endocrine therapy are recommended to receive endocrine therapy alone or endocrine therapy plus targeted ...

It’s a call to action for all of us to raise awareness, prioritize early ... breast cancer. Diet is another key factor. Processed foods, unhealthy fats, and artificial chemicals can disrupt ...

One in eight women in the U.S. will be diagnosed with breast cancer at some point in their ... radiation and/or hormone therapy. Write down all of your questions and bring them to every doctor ...

Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Breast Cancer: An Open-Label ... The mention of any product, service, or therapy in this ...